whatimpact is a social impact technology entity that uses AI and specific reporting tools to match charities and social enterprises, termed 'Recipients', with donor companies and grant-makers, termed 'Supporters' to ensure efficiency and transparency in Corporate Social Responsibility (CSR) and grant-making. whatimpact aspires to become a contender in the CSR segment that is estimated to be worth over £76 billion in reputational value to UK corporates. The business has onboarded 20 companies and 120 charities/Social Enterprises in Q1 2021 including EY, Brewin Dolphin, and Engie. whatimpact has a further 500 charities/social enterprises and 45 corporates in the pipeline. Its subscriptions range from £100/month to £2,000/month. It will use the investment to develop its algorithm and datasets, engage in customer acquisition, and build its leadership team.
days to go:
Expired
investment:
£375,002
Wise Analytics Group uses data to help companies, consumers and brands make better connections and more benefitial choices. They are a leader in terms of media analytics in the beauty sector, using a range of tools, technology and experience to create a product, market and consumer insight. Wise Analytics group have clients such as L'Oreal and Estee lauder. They are now looking to expand into other locations.
days to go:
Expired
investment:
Withheld
Zap and Go have created ultra fast technology for cordless and hand held devices by using Carbon-Ion technology which result in ultra-fast charging, taking 5 minutes or less. The technology is part derived from Oxford University and in part developed independently by Zap&Go's own scientists.
days to go:
Expired
investment:
£1,353,551
Zentraxa is focused on precision bioengineering to produce peptides with predictable properties tailored towards purpose. The company points out that peptides are amino acids that are the building blocks of certain proteins needed by the skin, like collagen and elastin. It has come out with a synthetic biology platform, Zentide, that designs, produces and tests novel peptides. Zentraxa argues that Zentide can circumvent previously existing bio-design limits imposed by conventional peptide synthesis and produce tailor-made biomaterials for healthcare, personal care and industrial uses. Zentraxa is initially targeting healthcare with its first biomaterial, a debondable adhesive, for use in wound care. The company asserts that the material has other uses such as cosmetics and industrial applications due to its ability to bond strongly while still being easily and painlessly removable. Zentraxa will use the investment to create a portfolio of other biomaterials for licensing to global businesses in the health and industrial sectors via its Zentide platform.
days to go:
Expired
investment:
£1,040,000
